Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31601570 | 1.00 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL30372051 | 0.84 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL655582 | 0.84 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL846330 | 0.83 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL846331 | 0.83 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL31536142 | 0.82 | CA12 (0.49) | MAPK1L3MBTL1ALDH1A1CA1CA2 | |
| SCHEMBL2622774 | 0.82 | CA12 (0.49) | MAPK1L3MBTL1ALDH1A1CA1CA2 | |
| SCHEMBL31003291 | 0.80 | KCNJ1 (0.42) | KDM4EL3MBTL1RAB9AKMT2AMAPT | |
| SCHEMBL932013 | 0.80 | KCNJ1 (0.42) | KDM4EL3MBTL1RAB9AKMT2AMAPT | |
| SCHEMBL9000473 | 0.80 | MAPK1 (0.56) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240542-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-3240543-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-11974999-B2 | Bruton's tyrosine kinase inhibitors | Liao, Xibin (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4229050-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116547279-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-110494433-B | Bruton's tyrosine kinase inhibitors | 廖细斌 | 2023-03-17 | — | — | CN | disclosed |
| US-11554118-B2 | Bruton's tyrosine kinase inhibitors | Liao, Xibin (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012151158-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2474544-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474543-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2433938-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | TPH1, HDAC1, HDAC2 | MAPK1 787/4885KDM4E 2195/4885L3MBTL1 2006/4885 |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MAPK1 707/4885KDM4E 3398/4885L3MBTL1 3343/4885 |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | CYP3A7, CYP11B2, CYP11B1 | MAPK1 2964/4885KDM4E 3888/4885L3MBTL1 4821/4885 |
| US-11974999-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | MAPK1 333/4885KDM4E 1320/4885L3MBTL1 1426/4885 |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | MAPK1 691/4885KDM4E 3799/4885L3MBTL1 1461/4885 |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | MAPK1 747/4885KDM4E 4721/4885L3MBTL1 699/4885 |
| US-11554118-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | MAPK1 333/4885KDM4E 1320/4885L3MBTL1 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.